Chronic Radiation Induced Bowel Toxicity Study

  • Recruiting
  • Observational
  • Procedure
  • The Christie NHS Foundation Trust
  • 18 Years -


Study Purpose

In the UK over 22,000 people undergo pelvic radiotherapy treatment per year, for several types of cancers including prostate cancer. The investigators want to investigate whether there are any differences in the bacteria in the bowel in patients with prostate cancer and whether these change during treatment. The aim of this study is to analyse the bacteria from the stool of patients undergoing radiotherapy for prostate cancer. The investigators will also look for any changes in the urine, blood and using rectal swabs that might be a surrogate for what is happening in the gut at the same time. They will collect food frequency/ food diary information for each patient alongside health questionnaires. The investigators aim to recruit approximately 50 patients diagnosed with prostate cancer due to undergo radiotherapy over a two year period. Patients will be recruited across 2 sites (Rosemere Cancer Centre, Lancashire Teaching Hospitals Trust and The Christie NHS Foundation Trust).

Intervention

Procedure : Procedure - blood, urine and stool sample collection


Eligibility Requirements

info icon Male, aged ≥ 18; no upper age limit and able to give informed consent.

info icon Newly diagnosed patients with, histologically confirmed, localised, intermediate to high-risk prostate cancer (T2b -T4a N0 M0).

info icon Patients to be treated with prostate radical radiotherapy IMRT (60Gy in 20# with curative intent) 4-week regimen.

info icon Performance status - ECOG 0-2.

info icon Had received systemic antibiotics (intravenous, intramuscular, or oral) within 2 months before enrolment.

info icon Had received cytotoxic or immunosuppressive therapies within 6 months of enrolment, including chemotherapy or immunotherapy.

info icon Had consumed large doses of commercial probiotics (greater or equal to 108 CFU per day) within 12 months of enrolment (such as Actimint®, CranProBio®, ImmunoProBio®, among others).

info icon Patients with diagnosed inflammatory bowel disease or coeliac disease

info icon Patients with previous colorectal cancer

info icon Patients who have undergone colectomy (total or subtotal)

info icon Patients with a history of diverticulitis (uncomplicated diverticular disease permitted)

Recruiting status

Recruiting

Estimated enrollment

50

 
Study start date

Nov 19, 2024

Study end date

Jul 31, 2027

Last updated

Mar 23, 2025

Primary purpose

N/A

Design

Observational

Intervention

Procedure

Study phase

N/A

Allocation

N/A

 

Sponsor:

The Christie NHS Foundation Trust

Collaborator:

University of Manchester

Lancashire Teaching Hospitals NHS Foundation Trust

Investigator:

N/A

NCT06640959

Clinic Location Investigator Distance RECRUITING STATUS Contact